Aquestive touts PhII data — and speed — in potential EpiPen replacement candidate
A New Jersey biotech specializing in drug delivery via oral film is reporting new Phase II data, setting a countdown to have it before the FDA by end of 2023.
Aquestive Therapeutics announced new data Tuesday for its candidate AQST-109, an oral film using a prodrug of epinephrine to treat anaphylactic shock from an allergic reaction.
Per the biotech, a readout of the EPIPHAST II trial was to compare one dose of AQST-109 — basically a patch — to a dose of an EpiPen at 0.3 mg, and an intramuscular injection of 0.3mg of epinephrine that wasn’t EpiPen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.